FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for EYLEA (aflibercept) submitted by Regeneron Pharmaceuticals, Inc. The action updates labeling and/or indications for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

SUPPL AP for EYLEA (AFLIBERCEPT)